Ethical Dilemma with Stakeholders
You're the CEO of a pharmaceutical company. Your best-selling drug ($2B annual revenue, used by 4 million patients for chronic pain) has…
As CEO, my priority is to protect the patients, the company’s long-term viability, and my own ethical integrity. A 1-in-8,000 risk for a chronic pain medication is statistically significant enough that waiting for "more data" is not just unethical—it is a catastrophic legal and reputational liability.Read the full answer
48-Hour Action Plan: Patient Safety First, Managed Transparency Second Core Decision (Stated Up Front) We report to regulators immediately—voluntarily—and we disclose on the earnings call. The math is brutal and clear: ~500 patients could develop liver failure over 5 years at current prescribing rates (4M ÷ 8,000).Read the full answer